Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
IGM Biosciences, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
IGMS
Nasdaq
2836
igmbio.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for IGM Biosciences, Inc.
Down -76.91% in 4 Weeks, Here's Why IGM Biosciences (IGMS) Looks Ripe for a Turnaround
- Feb 5th, 2025 2:35 pm
IGM Biosciences downgraded to Hold from Buy at Jefferies
- Jan 11th, 2025 3:55 pm
IGM Biosciences Shares Drop 68% as Company Halts Key Programs and Cuts Workforce
- Jan 10th, 2025 5:43 pm
IMG Biosciences enacts massive lay-offs after Phase I trial failure
- Jan 10th, 2025 12:55 pm
IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs
- Jan 9th, 2025 6:00 pm
IGM’s autoimmune pivot backfires as top drug disappoints in testing
- Jan 9th, 2025 3:00 pm
IGM Biosciences Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
- Nov 10th, 2024 12:06 pm
IGM Biosciences, Inc. (IGMS) Reports Q3 Loss, Tops Revenue Estimates
- Nov 8th, 2024 1:00 pm
IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update
- Nov 8th, 2024 12:00 pm
IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans
- Nov 7th, 2024 11:34 am
IGM Biosciences to Present at Three Upcoming Investor Conferences
- Nov 4th, 2024 12:00 pm
Top 1% Biotech, IGM Biosciences, Plummets On Scrapped Drug, C-Suite Makeover
- Oct 1st, 2024 8:03 pm
IGM Biosciences' New Found Focus: Pivots From Cancer To Autoimmune Diseases, Names New CEO
- Oct 1st, 2024 3:40 pm
IGM lays off staff in autoimmune pivot; Metsera ramps up obesity drug supply
- Oct 1st, 2024 12:00 pm
IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity
- Sep 30th, 2024 8:01 pm
While shareholders of IGM Biosciences (NASDAQ:IGMS) are in the black over 1 year, those who bought a week ago aren't so fortunate
- Sep 27th, 2024 10:54 am
IGM Biosciences (IGMS) Surges 11.6%: Is This an Indication of Further Gains?
- Sep 18th, 2024 1:33 pm
IGM Biosciences to Present at the Stifel 2024 Virtual Immunology and Inflammation Summit
- Sep 10th, 2024 8:05 pm
All You Need to Know About IGM Biosciences (IGMS) Rating Upgrade to Buy
- Aug 22nd, 2024 4:00 pm
IGM Biosciences, Inc. (IGMS) Reports Q2 Loss, Lags Revenue Estimates
- Aug 14th, 2024 12:00 pm
Scroll